Key Takeaway: Collegium Pharmaceuticals reported its financial results for the second quarter of 2026, highlighting a successful acquisition of AZSTARYS, which enhances its ADHD product offerings. The company achieved net revenues of $199.9 million, reflecting a 6% increase compared to the previous year. Notably, JORNAY PM saw a significant revenue growth of 41%, reaching $46.1 million.
Market Sentiment Analysis
POSITIVE FACTORS
Acquisition of AZSTARYS strengthens ADHD portfolio.
Quarterly net revenues increased by 6% year-over-year.
JORNAY PM quarterly net revenue rose by 41%.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
0.4%
average across 3 past catalysts
Lead asset
Evolocumab
Phase 3 · Sars-CoV-2 Infection
Full Press Release Details
– Completed Acquisition of AZSTARYS ®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS
Frequently Asked Questions
What were Collegium's net revenues for Q2 2026?
Collegium reported net revenues of $199.9 million for Q2 2026.
How much did JORNAY PM revenue increase?
JORNAY PM revenue increased by 41% year-over-year, totaling $46.1 million.
What acquisition did Collegium complete?
Collegium completed the acquisition of AZSTARYS, enhancing its ADHD portfolio.
What was the year-over-year revenue growth?
Collegium's revenue grew by 6% compared to the previous year.